EUCTR2015-002147-34-HU进行中（未招募）1 期
A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 55-79 years old (inclusive);
- •2. = 8 years of education (any type of schooling);
- •3. Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol;
- •4. Evidence of early AD, as defined by all of the following:
- •a. Memory complaint by subject or study partner that is verified by a study partner;
- •b. Objective memory impairment for age, documented by scoring below the
- •education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph
- •Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25):
- •i. = 8 for 16 or more years of education, or
- •ii. = 4 for 8-15 years of education;
- •c. Essentially preserved general cognitive function;
- •d. Largely intact functional activities;
- •e. Not demented;
- •5. CSF biomarker results consistent with early AD, including CSF Aß-42 levels = 180 pg/mL and = 690 pg/mL;
- •6. Clinical Dementia Rating (Global) = 0.5; Memory Box Score must be at least 0.5;
- •7. Must be fluent in the language of the cognitive testing material being administered;
- •8. Stability of permitted medications for 4 weeks prior to study entry; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for duration of study;
- •9. Visual and auditory acuity adequate for neuropsychological testing;
- •10. Good general health with no diseases expected to interfere with the study;
- •11. Must provide written informed consent for APOe4 genotype testing;
- •12. Must provide written informed consent for CSF sampling.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 400
排除标准
- •1. Any significant neurological disease other than suspected incipient AD, such as Parkinson’s disease, multi-infarct dementia, Huntington’s disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder,subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities;
- •2. Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 1 year, which could lead to difficulty complying with the protocol);
- •3. History of schizophrenia or bipolar disorder (DSM-IV criteria);
- •4. History of alcohol or substance abuse or dependence within the past 3 years (DSM-IVcriteria);
- •5. Currently taking medications that could lead to difficulty complying with the protocol;
- •subjects must be on a stable dose of current medications for 4 weeks prior to study entry; with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on stable dose for at least 12 weeks prior to study entry;
- •6. Investigational agents are prohibited one month prior to entry and for the duration of the trial;
- •7. Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);
- •8. Currently taking cromolyn, or have taken cromolyn, within the past 12 months;
- •9. Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis, or other chronic inflammatory diseases (chronic” defined as 3200 mg/day for > two weeks);
- •10. Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of strokeand/or other recommended uses;
- •11. Allergy to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®,etc.);
- •12. Allergies to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin, including Stevens-Johnson syndrome;
- •13. Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs; (examples: Stage III-IV COPD, emphysema);
- •14. Uncontrolled chronic asthma;
- •15. Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC <
- •predicted value for subject AND FEV1 < 70% of predicted value, indicating moderate or severe respiratory obstruction;
- •16. Taking inhaled protein products on a chronic basis (such as insulin, PTH, etc.)
- •17. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol;
- •18. Pregnancy or lactation for female subjects of child-bearing potential (i.e., < two years post-menopausal or not surgically sterile)
- •19. For sexually active male subjects, unwillingness or incapability of using appropriate contraception methods;
- •20. Severe renal or hepatic impairment.
研究者
相似试验
进行中（未招募）
1 期
A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.Early stage of Alzheimer's Disease.MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2015-002147-34-BGAZTherapies, Inc.600
进行中（未招募）
1 期
A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.EUCTR2015-002147-34-CZAZTherapies, Inc.600
进行中（未招募）
1 期
A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.Early stage of Alzheimer's Disease.MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2015-002147-34-PLAZTherapies, Inc.600
已完成
3 期
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's DiseaseAlzheimer's DiseaseNCT02547818AZTherapies, Inc.620
进行中（未招募）
3 期
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone LymphomaFollicular Lymphoma, Marginal Zone LymphomaJPRN-jRCT2021210065Eiji Ueda618